Your trusted source for investing success

Tag: in vitro

Tech Forecast and Promising Tech Stocks To Buy in 2017

Learn about breakthrough technology about to impact lives around the globe. We cover the entire industry in our FREE investor’s report.   Gain Access
DelMar Pharmaceuticals Initiates Phase 2 Clinical Trial in Newly Diagnosed MGMT-unmethylated Glioblastoma Multiforme

DelMar Pharmaceuticals Initiates Phase 2 Clinical Trial in Newly Diagnosed MGMT-unmethylated Glioblastoma Multiforme

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced the initiation of a Phase 2 clinical trial for its lead agent VAL-083 in newly diagnosed MGMT-unmethylated glioblastoma multiforme (GBM). The biomarker-driven clinical trial will explore safety and efficacy of chemoradiation with VAL-083 as

DelMar Pharmaceuticals Receives Approval from China’s Human Genetic Resources Administration to Initiate Phase 2 Clinical Trial in Newly Diagnosed GBM

DelMar Pharmaceuticals Receives Approval from China’s Human Genetic Resources Administration to Initiate Phase 2 Clinical Trial in Newly Diagnosed GBM

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the Human Genetic Resources Administration of China (HGRAC), has approved the Company’s application to initiate a Phase 2 safety and efficacy study of its lead product candidate VAL-083 in newly diagnosed MGMT-unmethylated glioblastoma

DelMar Pharmaceuticals Announces Completion of First Site Initiation Visit for STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM

DelMar Pharmaceuticals Announces Completion of First Site Initiation Visit for STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced the completion of the first site initiation visit at the Dent Neurological Institute (“Dent”) for its pivotal Phase 3 Study in Temozolomide-Avastin (bevacizumab) Recurrent GBM (“STAR-3”).  Site initiation visits are generally the final step before patient enrollment.

The

Tech Forecast and Promising Tech Stocks To Buy in 2017

Learn about breakthrough technology about to impact lives around the globe. We cover the entire industry in our FREE investor’s report.   Gain Access
Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
5 Top Weekly NASDAQ Tech Stock: Reports on Bitcoin Ban from China

URL: https://investingnews.com/daily/tech-investing/data-investing/weekly-nasdaq-tech-stocks/